



**Date: 20 December 2018**

**Sydney, Australia**

**ASX: NOX**

**Noxopharm Limited**

ABN 50 608 966 123

**Registered Office  
and  
Operational Office:**

Suite 3, Level 4  
828 Pacific Highway  
Gordon NSW 2072  
Australia

**Board of Directors**

**Mr Peter Marks**

Chairman  
Non-Executive  
Director

**Dr Graham Kelly**

Chief Executive Officer  
Managing Director

**Dr Ian Dixon**

Non-Executive  
Director

**Mr John Moore**

Non-Executive  
Director

ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

## **NOX Receives \$3.26M Federal Govt R&D Rebate**

**SYDNEY, December 20, 2018**, Noxopharm (ASX: NOX) announces that it has received \$3.264M cash rebate as part of the Federal Government's R&D Tax Incentive Scheme.

Graham Kelly Ph.D., Noxopharm Chief Executive Officer, said, "This rebate means that we will finish the calendar year with just over \$10M in cash, putting the Company in a solid financial position as we enter 2019 and a busy clinical agenda. Having recently had confirmation of the anti-cancer potential of Veyonda<sup>®</sup> as both a radio-enhancer and chemo-enhancer, these funds will go towards expediting the clinical development of Veyonda<sup>®</sup> as it enters its final stages of development next year."

Greg van Wyk MD., Noxopharm Chief Medical Officer, said, "Our clinical program next year for Veyonda<sup>®</sup> is extremely exciting and appropriately ambitious. It is an integrated strategy focused on bringing Veyonda<sup>®</sup> to market in the shortest time possible, plus maximising its market uptake following approval. Apart from completing the DARRT-1 and LuPIN-1 studies next year, we are planning on an additional 4 clinical studies. These include a pharmacokinetic study as part of an Investigational New Drug application to the U.S. Food and Drug Administration, commencing additional DARRT studies in sarcoma, laying the foundations for expansion of the DARRT program into additional tumour types such as lung cancer and brain cancer, and preparing for the final DARRT study in prostate cancer."

### **About Veyonda<sup>®</sup>**

Veyonda<sup>®</sup> (previously known as NOX66) is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to preserve the anti-cancer activity of idronoxil in the body and to enhance its drug-like behaviour. Idronoxil inhibits sphingosine kinase, a key regulator of cell pro-survival mechanisms, and which is over-expressed in many cancer cells. Loss of pro-survival signaling via inhibition of sphingosine-1-phosphate production, leads to loss of multiple pro-survival functions including DNA repair mechanisms. These biological effects enable idronoxil to act as a potent enhancer of both radiation and cytotoxic chemotherapies. Idronoxil also is an immuno-oncology drug, activating the body's innate immune system, particularly natural killer (NK) cells.

### **About DARRT**

The Company's DARRT (Direct and Abscopal Response to Radiotherapy) Program is testing the ability of Veyonda<sup>®</sup> to increase tumour response to palliative dosages of radiotherapy. The DARRT treatment regimen entails a 5-day course of radiotherapy (20-30 Gy) in 5 fractionated dosages targeting 1-2 larger tumours, and the Veyonda<sup>®</sup> administered daily for up to 3 weeks. The rationale of DARRT is to combine the radio-enhancing

properties of Veyonda<sup>®</sup> that stem from its inhibition of sphingosine-1-phosphate activity, with its ability to stimulate the body's first line immune defense cells against cancer. The clinical outcome being sought is greater shrinkage of irradiated tumours and shrinkage of all non-irradiated tumours (abscopal response).

#### **About Noxopharm**

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney, Hong Kong and New York. The Company has a primary focus on the development of drugs based on an isoflavonoid chemical structure. Veyonda<sup>®</sup> is the first pipeline product, with 3 other drug candidates for non-oncology indications under development in a subsidiary company.

#### **Investor & Corporate Enquiries:**

Prue Kelly

M: 0459 022 445

E: [info@noxopharm.com](mailto:info@noxopharm.com)

#### **Company Secretary:**

David Franks

T: +61 2 9299 9690

E: [David.Franks@atomicgroup.com.au](mailto:David.Franks@atomicgroup.com.au)

#### **Media Contact:**

Allison Blum, Ph.D.

LifeSci Public Relations

T: +1 516 655 0842

E: [allison@lifescipublicrelations.com](mailto:allison@lifescipublicrelations.com)

[www.noxopharm.com](http://www.noxopharm.com)

#### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.